Last --
Change Today 0.00 / 0.00%
Volume 0.0
All times are local (Market data is delayed by at least 15 minutes).

nobel biocare holding ag-reg (NOBN) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

nobel biocare holding ag-reg (NOBN) Related Businessweek News

No Related Businessweek News Found

nobel biocare holding ag-reg (NOBN) Details

Nobel Biocare Holding AG operates in the field of implant-based dental restorations worldwide. It offers dental implants for various indications, bone types, and surgical protocols; high-precision individualized prosthetics and CAD/CAM systems for every indication, from a single tooth to edentulous jaws, on natural teeth and implants; and machined and TiUnite implants. The company also provides a range of individualized CAD/CAM abutments and a portfolio of prefabricated temporary and final abutments; biomaterials for soft tissue and bone regeneration under the creos brand; and removable and fixed implant-supported restorations. In addition, it offers NobelClinician software for enhanced diagnostics and treatment planning; and NobelGuide, a treatment concept for diagnostics, prosthetic-driven treatment planning biomaterials and guided implant surgery. Nobel Biocare Holding AG provides training and education, as well as a range of practice support and patient information materials to its customers. The company markets its products to dental healthcare professionals comprising oral surgeons, general practitioners, specialists, and laboratories. Nobel Biocare Holding AG was founded in 1981 and is headquartered in Kloten, Switzerland.

2,518 Employees
Last Reported Date: 04/29/14
Founded in 1981

nobel biocare holding ag-reg (NOBN) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.2.0M
Compensation as of Fiscal Year 2013.

nobel biocare holding ag-reg (NOBN) Key Developments

Nobel Biocare Announces Executive Changes

Nobel Biocare announced that it is reducing its Executive Committee by two members, effective July 4, 2014. Walter Ritter, Executive Vice President Global Human Resources, has announced his desire to retire by May 2015. Jörg von Manger-Koenig, Executive Vice President Global Legal and Compliance and Group General Counsel, will, in addition to his current responsibilities, also assume Executive Committee responsibility for Global Human Resources. Petra Rumpf, Executive Vice President Corporate Development will be leaving Nobel Biocare to pursue other opportunities outside the company. Corporate Development responsibilities will shift to Oliver Walker, Chief Financial Officer, and responsibilities for the Foundation for Oral Rehabilitation (FOR) will transfer to Jörg von Manger-Koenig.

Nobel Biocare Reports Revenue Results for the First Quarter of 2014

Nobel Biocare reported revenue results for the first quarter of 2014. For the period, the company reported revenue of €138.8 million, and representing increase of 3% from €141.5 million for the same period a year ago.

Nobel Biocare Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Provides Earnings Guidance for the Full Year 2014

Nobel Biocare reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, net profit attributable to owners of the company was EUR 12.5 million compared to EUR 13.3 million achieved a year ago. The decline is fully attributable to the adverse currency impact and a lower net financial result compared to prior year. Net cash from operating activities was EUR 15.2 million, slightly up from last year's EUR 14.0 million. Revenue was EUR 138.8 million against EUR 141.5 million a year ago. Operating profit (EBIT) was EUR 19.0 million against EUR 18.9 million a year ago. Profit before tax was EUR 16.6 million against EUR 18.2 million a year ago. Diluted and basic earnings per share were EUR 0.10 against EUR 0.11 a year ago. Purchases of property, plant and equipment was EUR 1,605,000 against EUR 1,674,000 a year ago. Purchases of intangible assets were EUR 798,000 against EUR 1,278,000 a year ago. Return on average equity was 12.8% against 14.6% a year ago. For the full year 2014, the company expects revenue to grow around 3% to 4% and to improve the EBIT margin excluding realignment costs by about 100 bps (CER) from 12.1% in 2013.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOBN:VX SFr.0.00 CHF 0.00

NOBN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
DENTSPLY International Inc $47.46 USD -0.04
Osstem Implant Co Ltd 30,900 KRW +2,800
Straumann Holding AG SFr.211.30 CHF -1.40
Zimmer Holdings Inc $103.79 USD +0.12
View Industry Companies

Industry Analysis


Industry Average

Valuation NOBN Industry Range
Price/Earnings 33.1x
Price/Sales 2.4x
Price/Book 4.2x
Price/Cash Flow 33.0x
TEV/Sales 1.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOBEL BIOCARE HOLDING AG-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at